Mereo Biopharma Group PLC Schedule 13G passive stakes

EcoR1 Capital, LLC and related entities have reported beneficial ownership of 0.6% of Mereo BioPharma Group plc's ordinary shares.

Investment firm EcoR1 Capital and Oleg Nodelman have reported an 8.4% beneficial ownership stake in Mereo BioPharma Group plc.

Bank of America Corporation has reported a beneficial ownership of 5.1% in Mereo BioPharma Group plc, holding 40,976,460 ordinary shares.

Janus Henderson Group plc filed an amended Schedule 13G, reporting a 0.0% beneficial ownership in Mereo Biopharma Group PLC as of December 31, 2025.

Frazier Life Sciences and its affiliated entities have reported a 0.0% beneficial ownership in Mereo BioPharma Group plc, indicating a full divestment of their previous stake.

EcoR1 Capital, LLC and its affiliates have reported a 9.4% beneficial ownership stake in Mereo BioPharma Group plc, held passively as of January 2, 2026.

683 Capital Management, LLC and its affiliates have reported a passive beneficial ownership of 8.18% in Mereo BioPharma Group plc.

Janus Henderson Group plc and its affiliates reported a beneficial ownership of 10.2% in Mereo BioPharma Group PLC's American Depositary Shares in an amended Schedule 13G filing.

Mangrove Partners IM, LLC and Nathaniel August have reduced their beneficial ownership in Mereo BioPharma Group plc to 4.9%, signaling a partial divestment.

Frazier Life Sciences funds updated their beneficial ownership in Mereo BioPharma Group plc, clarifying share attribution and aggregate holdings.

Janus Henderson Group PLC and its affiliate report increased beneficial ownership in Mereo BioPharma Group PLC, now holding 11.1% of American Depositary Shares.

Northpond Ventures entities and Michael P. Rubin have disclosed beneficial ownership of 6.9% of Mereo BioPharma Group plc's ordinary shares, totaling 54,521,000 shares.

Rock Springs Capital Management LP and its affiliates have filed an amended Schedule 13G, reporting a 4.2% beneficial ownership stake in Mereo BioPharma Group PLC as of March 31, 2025.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a combined beneficial ownership of 14.3% in Mereo BioPharma Group PLC's American Depositary Shares as of March 31, 2025.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has filed an amended Schedule 13G disclosing a 1.07% beneficial ownership stake in Mereo BioPharma Group plc.

Frazier Life Sciences Public Fund, L.P. and affiliated entities, along with key individuals, have disclosed a collective beneficial ownership of 5.1% in Mereo BioPharma Group plc, held for passive investment purposes.

Adage Capital Management, L.P. and its principals have disclosed a passive beneficial ownership of 5.62% in Mereo BioPharma Group plc, holding 43,575,065 ordinary shares as of December 31, 2024.